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Abstract
Background: Preterm birth (birth before 37 weeks of gestation) is a major problem in obstetrics and affects an
estimated 15 million pregnancies worldwide annually. A history of previous preterm birth is the strongest risk factor
for preterm birth, and recurrent spontaneous preterm birth affects more than 2.5 million pregnancies each year. A
recent meta-analysis showed possible benefits of the use of low dose aspirin in the prevention of recurrent
spontaneous preterm birth. We will assess the (cost-)effectiveness of low dose aspirin in comparison with placebo
in the prevention of recurrent spontaneous preterm birth in a randomized clinical trial.
Methods/design: Women with a singleton pregnancy and a history of spontaneous preterm birth in a singleton
pregnancy (22–37 weeks of gestation) will be asked to participate in a multicenter, randomized, double blinded,
placebo controlled trial. Women will be randomized to low dose aspirin (80 mg once daily) or placebo, initiated
from 8 to 16 weeks up to maximal 36 weeks of gestation. The primary outcome measure will be preterm birth,
defined as birth at a gestational age (GA) < 37 weeks. Secondary outcomes will be a composite of adverse neonatal
outcome and maternal outcomes, including subgroups of prematurity, as well as intrauterine growth restriction
(IUGR) and costs from a healthcare perspective. Preterm birth will be analyzed as a group, as well as separately for
spontaneous or indicated onset. Analysis will be performed by intention to treat. In total, 406 pregnant women
have to be randomized to show a reduction of 35% in preterm birth from 36 to 23%. If aspirin is effective in
preventing preterm birth, we expect that there will be cost savings, because of the low costs of aspirin. To evaluate
this, a cost-effectiveness analysis will be performed comparing preventive treatment with aspirin with placebo.
Discussion: This trial will provide evidence as to whether or not low dose aspirin is (cost-) effective in reducing
recurrence of spontaneous preterm birth.
Trial registration: Clinical trial registration number of the Dutch Trial Register: NTR 5675. EudraCT-registration
number: 2015-003220-31.
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Background
Preterm birth (<37 weeks of gestation) is the most com-
mon cause of neonatal morbidity and mortality world-
wide. Worldwide in 2010 an estimated 14.9 million
neonates were born preterm of whom 1.6 million were
born < 32 weeks of gestation [1].
Preterm birth accounts for 70% of all neonatal mortality
and for 40% of childhood neurological morbidity [2]
resulting in a tremendous impact on both the child and its
parents. The effects of preterm birth are not restricted to
the neonatal period. Prematurity is a risk factor for devel-
opmental problems later in life. The risk of complications
is directly proportional to the severity of prematurity;
adverse neonatal outcome declines from 77% at 24–27
weeks to less than 2% beyond 34 weeks [2, 3].
Gestational age at birth determines to a large extent the
health prospects of the neonate. The increased physical
and mental health problems for preterm born children
result in increased health costs, leading to a considerable
economic burden for society [4].
One third of preterm births are due to medical inter-
vention because of maternal or fetal complications, while
two third of preterm births occurs after spontaneous
onset of the delivery [5]. The strongest risk factor associ-
ated with preterm birth is a previous preterm birth, with
a relative risk (RR) of 6.0 (95% CI 4.1 – 8.8) if the pre-
term birth was < 32 weeks in the index pregnancy and
RR 4.8 (95% CI 3.9–6.0) if birth was between 32 and
36 weeks [6]. Currently, the mostly used strategy for pre-
vention of recurrent spontaneous preterm birth is the
administration of progestagens, either natural progester-
one or 17 Alpha-hydroxyprogesterone. A Cochrane review
on the subject concluded that the use of progesterone is
associated with benefits in infant health and showed a re-
duction of preterm birth less than 37 weeks (10 studies;
1750 women; pooled RR 0.55, 95% CI 0.42 to 0.74) [7]. In
the largest trial on the subject a reduction from 55% to
36% (RR 0.66; 95% CI 0.54–0.81) was observed [8]. A re-
cent publication of a large trial showed that vaginal pro-
gesterone was not associated with reduced risk of preterm
birth or composite neonatal adverse outcomes [9]. Thus,
the literature on the subject is ambiguous. Despite the use
of progestagens, at least one third of the women will
have a recurrent spontaneous preterm birth, suggest-
ing that multiple underlying mechanisms contribute
to its pathogenesis [10].
An increasing body of evidence suggests that utero-
placental ischemia plays a major role in the genesis of
spontaneous preterm labour. Placental vascular path-
ology and placental bed pathology are common findings
in women with a spontaneous preterm birth [10–13].
Also, abnormal angiogenic/anti-angiogenic profile in
maternal plasma is seen in a subset of patients with
spontaneous preterm birth [14], and increased resistance
at midtrimester Doppler measurement of uterine artery
flow provides an increased risk of spontaneous preterm
birth [15]. In addition, women with a spontaneous pre-
term birth have an increased risk of developing cardio-
vascular disease later in life [16, 17]. These findings
suggest an overlap with other ischemic placental diseases
such as preeclampsia.
In the light of the possible similar underlying mechan-
ism, preventive measures for ischemic placental disease
might also be effective in preventing recurrent spontan-
eous preterm birth. The most successful intervention in
the prevention of recurrent preeclampsia is low dose
acetylsalicylic acid (aspirin or ASA). Aspirin acts as a
thrombocyte aggregation inhibitor and it reduces prosta-
glandin synthesis through inhibition of the enzyme cyclo-
oxygenase, thereby having an anti-inflammatory effect. A
recent meta-analysis showed a reduction of preeclampsia
with a RR 0.47 (0.34-0.65) if aspirin was initiated before
16 weeks of gestation [18]. Interestingly, a marked reduc-
tion in total preterm births was also observed with a RR of
0.22 (0.0–0.49). This reduction in preterm birth could not
be fully explained by the reduction of indicated preterm
birth by clinicians for medical reasons, suggesting also a
decrease in spontaneous preterm births associated with
the use of aspirin. A recently published Individual Partici-
pant Data (IPD) meta-analysis specifically looked at rates
of spontaneous preterm birth in women receiving anti-
platelet agents for the indication of high risk of pre-
eclampsia [19]. Women assigned to aspirin treatment
compared to placebo or no treatment had a lower risk of
spontaneous preterm birth <34 weeks (RR 0.86, 95% CI
0.76–0.99) and <37 weeks (RR 0.93, 95% CI 0.86–0.996).
Furthermore, in other groups of patients where
aspirin is used to improve pregnancy outcomes there is
also evidence suggesting an effect on spontaneous pre-
term birth.
A recent IPD meta-analysis on preconception started
low-dose aspirin treatment in IVF patients found a
lower, though not statistically significant, incidence of
preterm birth in women with a singleton pregnancy after
adjustment for hypertensive pregnancy complications
(OR 0.52, CI 0.16–1.7) [20].
A Dutch randomized clinical trial on aspirin and low
molecular weight heparins in patients with recurrent
miscarriage showed the lowest incidence of preterm
birth in the aspirin group of 1.6%, versus 10.1% in the
combined (aspirin and Low Molecular Weight Heparin
(LMWH)) group and 4.3% in the placebo group [21].
Another recent randomized clinical trial, randomizing
women with one or two recent pregnancy losses be-
tween low dose aspirin and placebo, started preconcep-
tion and continued until 36 weeks of gestation, showed
a trend towards a lower spontaneous preterm birth rate
with a RR of 0.45, 95% CI 0.19 to 1.08 [22, 23].
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Aspirin is a safe intervention in pregnancy as a recent
review commissioned by the 'U.S. Preventive Services
Task Force' concluded [24]. In view of the potential
common underlying etiology of ischemic placental dis-
ease such as preeclampsia and spontaneous preterm
birth, the proven preventive effect of aspirin on pre-
eclampsia and the promising results in prevention of
spontaneous preterm birth in RCTs on IVF, miscarriage
and preeclampsia, our hypothesis is that aspirin adminis-
tered before 16 weeks of gestation onwards will reduce
recurrent spontaneous preterm birth. As this treatment
is at present not routine practice and as this hypothesis
has never been tested in a randomized clinical trial in
patients with a previous spontaneous preterm birth, we
designed a randomized clinical trial on the subject. The ef-
fect of aspirin on spontaneous preterm birth is tested best
in a high-risk population, being women with a previous
spontaneous preterm birth.
Methods/design
Aims
The objective of the study is to assess the (cost-)effective-
ness of low dose aspirin in comparison with placebo in
preventing preterm birth when initiated in early pregnancy
in women with a previous spontaneous preterm birth.
Design and setting
A multicenter, randomized, double blinded, placebo
controlled trial will be performed within the Dutch
Consortium for Healthcare Evaluation and Research in
Obstetrics and Gynecology (NVOG Consortium 2.0,
www.studies-obsgyn.nl).
Participant/eligibility criteria
Patients 18 years of age or older are eligible in case of a
singleton pregnancy between 8 and 16 weeks of gesta-
tion with a previous spontaneous preterm birth in a
singleton pregnancy, defined as birth at a gestational age
between 22 and 37 weeks. Spontaneous preterm birth
is defined as a preterm birth following spontaneous
contractions with intact membranes or preterm birth
after spontaneously ruptured membranes. Exclusion
criteria include women with previous indicated pre-
term births for maternal reasons such as preeclampsia
or HELLP-syndrome or for fetal reasons such as IUGR,
other indications for aspirin use, thrombocytopenia/
thrombocytopathy, major fetal malformations in current
pregnancy or in previous spontaneous preterm birth.
Procedures, recruitment, randomization and collection of
baseline data
Eligible women will be identified by the local research
coordinators and/or the staff of participating hospitals.
Women eligible for the trial will be counseled by ‘good
clinical practice’ (GCP) trained doctors, midwifes or re-
search nurses. After counseling and reading the patient
information form, patients will be asked for written
consent. We will provide patient information in Dutch
as well as in English. After informed consent, patient
data will be entered in a web-based database, which will
also facilitate randomization.
Women will randomly be double-blindly allocated to
either aspirin administration or placebo administration
in a 1:1 ratio: both participant and healthcare worker
will be unaware of what group the women is allocated.
Randomization will be performed centrally with the use
of a random 2 : 4 block design.
At study entry, baseline demographic, past obstetric
and medical history will be recorded into the web-based
Case Report Form (CRF) that is accessible through a
closed part of a central website, OpenClinica. Details of
delivery, maternal and neonatal assessments during preg-
nancy or post-partum are recorded in the CRF. The
collected data will be coded and processed with adequate
precautions to ensure patient confidentially.
Intervention
Eligible women will be randomized by a web-based cen-
tral randomization system to low dose aspirin 80 mg
one tablet a day or placebo one tablet a day, preferably
taken in the evening. Administration will be initiated be-
tween 8 and 16 weeks of gestation and will be continued
up to 36 weeks of gestation or up to delivery, whatever
comes first. Other preventive measures such as adminis-
tration of progesterone, cerclage or pessary will be pro-
vided according local protocols for prevention of
preterm birth derived from the national guidelines [25].
Follow up
All details on delivery, maternal and neonatal assess-
ments and admission during pregnancy are recorded in
the CRF that is accessible through the website. Mortality
and morbidity will be specified for the mother and the
child until date of discharge from hospital or 3 months
of corrected age. We plan long term follow-up of the chil-
dren at age of 24 and 60 months to examine (neuro-)
developmental outcomes.
Outcome measures
The primary outcome measure will be preterm birth, de-
fined as birth at a GA of less than 37 weeks. The most
important secondary outcome is a composite of poor
neonatal outcome (including bronchopulmonary dyspla-
sia (BPD), periventricular leucomalacia (PVL) > grade 1,
intraventricular hemorrhage (IVH) > grade 2, necrotizing
enterocolitis (NEC) > stage 1, retinopathy of prematurity
(ROP), culture proven sepsis and perinatal death). The
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individual components of the composite outcome will
also be assessed separately.
The diagnosis of BPD will be made at 36 weeks of
postmenstrual age, if a neonate has received supplemen-
tal oxygen for at least 28 days. Classification will take
place using an oxygen reduction test [26]. PVL > grade 1
and IVH > grade 2 will be diagnosed by repeated cranial
ultrasound by the neonatologist, according to the Papille
classification [27, 28]. NEC stage >1; will be diagnosed
and classified by the Bell staging criteria. ROP will be
classified conform the International Classification of
Retinopathy of Prematurity [29]. Culture proven sepsis is
defined as the combination of clinical signs and a posi-
tive blood culture. Distinction will be made between:
early onset sepsis (EONS) and late onset sepsis (LONS).
For EONS clinical suspicion and positive blood culture
suffices for a diagnosis. LONS will be diagnosed accord-
ing to the definition of Stoll [30] that also requires a
CRP blood level of >10 mg/L. Finally, perinatal death is
defined as death of a fetus or neonate at any time be-
tween a gestational age of ≥ 16 weeks and discharge.
Additional secondary neonatal outcomes are number
of days on ventilation support (mechanical ventilation
and/or respiratory support by Continuous Positive
Airway Pressure (CPAP)), infant respiratory distress syn-
drome (IRDS) that requires treatment with surfactant,
patent ductus arteriosus (PDA) that requires medical or
surgical treatment, cerebellar bleeding, days of admission
on the NICU, convulsions, asphyxia, proven meningitis,
pneumothorax and total days in hospital until 3 months
corrected age.
Furthermore, preterm birth rates at ≤ 28 weeks, ≤
32 weeks, ≤ 34 weeks of gestation will be assessed as a
group and will also be analyzed separately as spontan-
eous, indicated or as a combination. Growth restriction
will be analyzed and birth weight will be assessed both
continuous and < p10. Separate assessment of birth
weight will take place on fetal growth chart [31] and is
defined as estimated fetal weight < P10.
Maternal outcomes include maternal side effects,
maternal mortality, hospital admissions in general and
specifically due to threatened preterm labour with
need for treatment with tocolysis and or corticoste-
roids for antenatal fetal lung ripening. Maternal mor-
bidity due to hypertensive disease in pregnancy will be
defined according to the ACOG-guideline ‘hypertension in
pregnancy’ [32]. Pregnancy-induced hypertension will be
defined as: development of new hypertension ≥ 140/
90 mmHg measured twice after 20 weeks of gestation. Pre-
eclampsia will be defined as: hypertension ≥ 140/90 mmHg
measured twice after 20 weeks of gestation and proteinuria
(protein ≥ 300 mg/24 h) or thrombocytopenia (thrombo-
cytes < 150 x 10e9/L), impaired liver function or renal insuf-
ficiency. Eclampsia will be defined as: seizures in a
pregnancy complicated by preeclampsia. HELLP syndrome
will be defined as: as the presence of hemolysis, elevated
liver enzymes and low platelets with or without the pres-
ence of proteinuria of hypertension. Placental abruption
will be defined as: clinical diagnosis of (partial) detachment
of the placenta from the uterine wall [32].
Other maternal outcomes will be defined as follows:
gestational diabetes as onset of diabetes after 20 weeks
of gestation. The diagnosis of pulmonary edema will be
based on clinical findings, thromboembolic disease will
include both deep vein thrombosis and pulmonary
embolism, maternal infection or inflammation will be a
clinical diagnosis and major ante- or post-partum
hemorrhage (blood loss ≥ 1 liter) will also be assessed.
The core-outcomes for research concerning interven-
tions to prevent preterm birth as defined by the
CROWN-initiative [33] will be assessed where possible
to ensure that data from trials that assess prevention of
preterm birth can be compared and combined, for
example in future meta-analyses.
Costs will be measured from a healthcare perspective
using case record forms until 3 months of corrected age
of the infant. Costs will include costs of outpatient visits,
hospital admissions, and the delivery. For the valuation
of health care utilization, standard prices published in
the Dutch costing guidelines will be used. Alternatively,
hospital administration data or tariffs will be used if
necessary. Medication use will be valued using prices of
the Royal Dutch Society for Pharmacy.
Hypothesis generating subgroup analyses will be per-
formed for women with a previous preterm birth before
and after 30 and 34 weeks GA, a history of preterm birth
starting with contractions with intact membranes versus
preterm premature rupture of membranes (PPROM),
women additionally treated with progestagens versus no
additional treatment, women with a short cervix
(<25 mm before 24 weeks) in the current pregnancy and
women who started using the study-medication at less
than 12 weeks versus 12-16 weeks of gestation.
Statistical issues
Data-analysis
Data will be analyzed according to the intention-to-treat
principle. Participants will be kept in the study regard-
less of whether they decide to discontinue the study
medication unless they explicitly withdraw permission to
use their data. Because the results are all to be extracted
from the medical records of the participants, it is not
expected that there will be missing data. Best effort will
be made to retrieve the data. If still there is missing data,
this will be mentioned along with the reason. Baseline
characteristics of the groups will be presented using per-
centages, means with 95% confidence intervals (CI) and
medians with interquartile ranges, where appropriate.
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No interim analysis for efficacy will be performed, however
an independent Data Safety and Monitoring Committee
will be monitoring patient safety every 6 months, starting
9 months after the inclusion of the first patient.
The main outcome variable, ‘reduction in recurrent
preterm birth’, will be assessed by comparing the event
rates in the two groups using a chi-square test with a p-
value of 0.05. The main outcome will be presented as
absolute and relative risks (along with 95% confidence
intervals) and numbers needed to treat (if applicable).
The secondary outcome is poor neonatal outcome.
Categorical secondary outcomes will be assessed in the
same way as the primary outcome, except that Fisher’s
exact test will be used where appropriate. For continu-
ous secondary outcomes, differences between groups
will be assessed with the student’s t-test if the outcome
is normally distributed and with a non-parametric
Mann-Whitney U test if skewed. These outcomes will be
presented per group as means with standard deviation,
geometric means with 95% CI, or as median with inter-
quartile range, whichever appropriate.
A Kaplan–Meier plot of gestational age at delivery will
be presented and the difference gestational age at birth
between the study arms will be tested with the log-rank
test. Along with this plot, the percentage non-delivered
at 28, 30, 32, and 34 weeks will be presented per arm.
Sample size
A reduction of recurrent preterm birth from 36 to 23%
(a reduction of 35%) can be detected if 406 patients are
recruited (203 in each arm, power of 80%, (alpha-error
0.05). Because estimates are not consistent, the assump-
tion of the occurrence of recurrent preterm birth was
made based on the largest trial performed on prevention
of preterm birth using progesterone [8].
Economic analysis
The economic evaluation will be performed from a health-
care perspective. The primary outcome will be costs
(savings) per pre-term birth prevented. Missing cost and
effect data will be imputed using multiple imputation.
Cost and effect differences will be estimated using bivari-
ate regression models with adjustment for confounders
and effect modifiers if necessary. Bias-corrected acceler-
ated bootstrapping (5000 replications) will be used to as-
sess statistical uncertainty. Incremental cost-effectiveness
ratios (ICERs) will be calculated by dividing the difference
in costs by the differences in primary and secondary out-
comes between the groups. Cost-effectiveness acceptabil-
ity curves showing the probability that the intervention is
cost-effective in comparison with usual care for a range of
different ceiling ratios will also be estimated [34]. In a
budget impact analysis results from the economic
evaluation will be extrapolated to the national level. The
economic analysis will be published in a separate paper.
Serious adverse events
A data safety monitoring board is established to perform
ongoing safety surveillance. Serious adverse events will
be reported to the board every 6 months along with the
treatment arm. No interim analysis for efficacy will be
performed.
Confidentiality and data security
Linking personal data with randomization number can
only be done in the local clinics. Each participating clinic
receives a login name and password to gain access to the
web-secured database. The access is restricted to the
database of the clinic to which the password and login
name belongs. Full access to the entire database is
restricted to some members of the research staff.
Discussion
Recurrent spontaneous preterm birth remains a large
contributor to the perinatal morbidity and mortality as a
result of preterm birth, with a need for additional pre-
ventive methods. Based on research that points in the
direction of placental ischemia as a (partial) cause of
spontaneous preterm birth, interventions that improve
the placentation may be effective in reducing the num-
ber of (recurrent) spontaneous preterm birth. This study
is designed to provide evidence on the (cost-) effective-
ness of low dose aspirin in comparison with placebo in
preventing preterm birth in women with a history of
spontaneous preterm birth. Low dose aspirin is consid-
ered safe in pregnancy and is already widely embedded
in the obstetric practice for other indications. Therefore, if
aspirin is proven to be effective in reducing recurrent
spontaneous preterm birth, it would be easy to implement
in daily practice.
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